Wednesday 4 November 2026 Export NOVT’s income statement to Excel — free account

Novanta Inc.

NOVT Technology Scientific & Technical Instruments

Novanta Inc.’s revenue for fiscal 2025 (year ended December 2025) was $980.6 million, up 3.30% from fiscal 2024.

Revenue: +10.3%
EPS: +158.3%
Free cash flow: +391.8%
Total debt: −50.0%

Quarter to June 2026, against a year earlier

Revenue growth 5 yrs

144.88 2.61 −1.77%

Follow NOVT

Alert me

Market cap: $5.6B
P/E: 92.5×
Fwd P/E: 80.1×
Dividend yield: —
F-score: 5/9
Altman Z: 6.64
Beneish M: −2.25
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Novanta Inc. (NOVT) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
Automation Enabling Technologies	501	51.07%
Medical Solutions	480	48.93%
Gross margin		44.39%
Operating margin		9.59%
Pre-tax margin		7.10%

Revenue by product or service $m

Line	FY2010
Precision Motion And Technologies	181 63.27%
Laser Products	105 36.73%
Revenue	286

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Automation Enabling Technologies	501 51.07%	491 51.69%	499 56.62%	534 62.04%	—	—	—	—	—	—	—	—	—	—
Medical Solutions	480 48.93%	459 48.31%	382 43.38%	327 37.96%	262 37.08%	262 44.30%	271 43.35%	233 37.91%	183 35.12%	122 31.77%	125 33.38%	122 33.50%	90 28.49%	26 10.63%
Precision Medicine and Manufacturing	—	—	—	—	232 32.89%	200 33.80%	230 36.81%	249 40.59%	232 44.57%	174 45.26%	168 45.06%	178 48.73%	167 52.57%	159 65.07%
Robotics and Automation	—	—	—	—	212 30.03%	129 21.90%	124 19.84%	132 21.50%	106 20.31%	88 22.96%	81 21.56%	65 17.77%	60 18.94%	59 24.30%
Revenue	981	949	882	861	707	591	626	614	521	385	374	365	317	244

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012
Precision Medicine and Manufacturing	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Robotics and Automation	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Medical Solutions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and Other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010
UNITED STATES	519 52.93%	487 51.32%	418 47.44%	372 43.25%	271 38.32%	226 38.22%	254 40.61%	242 39.43%	221 42.31%	155 40.22%	155 41.44%	141 38.65%	108 34.04%	76 31.35%	103 33.78%	95 33.31%
Rest of Europe	137 14.01%	129 13.58%	137 15.54%	138 16.01%	139 19.65%	127 21.51%	130 20.71%	106 17.19%	81 15.54%	52 13.44%	48 12.92%	54 14.89%	46 14.42%	41 17.01%	48 15.72%	—
GERMANY	115 11.69%	123 12.98%	128 14.54%	134 15.53%	102 14.41%	84 14.18%	82 13.10%	88 14.33%	68 13.05%	56 14.54%	55 14.65%	59 16.19%	56 17.76%	33 13.46%	44 14.40%	—
Rest of Asia-Pacific	97 9.90%	107 11.28%	105 11.95%	102 11.80%	89 12.62%	74 12.59%	90 14.31%	104 16.98%	85 16.25%	60 15.62%	62 16.72%	59 16.13%	58 18.24%	65 26.77%	—	—
China	93 9.50%	85 8.91%	73 8.33%	97 11.29%	95 13.45%	71 11.95%	60 9.51%	66 10.81%	56 10.77%	44 11.49%	38 10.30%	41 11.18%	38 11.88%	21 8.61%	—	—
Other Countries	19 1.97%	18 1.94%	19 2.19%	18 2.12%	11 1.55%	9 1.55%	11 1.76%	8 1.26%	11 2.08%	18 4.69%	15 3.96%	11 2.95%	12 3.65%	7 2.79%	—	—
Asia Pacific	—	—	—	—	—	—	—	—	—	—	—	—	—	—	72 23.73%	83 28.88%
Japan	—	—	—	—	—	—	—	—	—	—	—	—	—	—	31 10.06%	33 11.47%
Other Country	—	—	—	—	—	—	—	—	—	—	—	—	—	—	7 2.32%	2 0.65%
Europe	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	73 25.70%
Revenue	981	949	882	861	707	591	626	614	521	385	374	365	317	244	304	286

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
Growth in bookings	Q1 FY2026	37.0%	—	—
Organic revenue growth	Q2 FY2026	9.30%	−2.10%	—
Overall book-to-bill ratio	Q1 FY2026	1.1×	—	—

	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024
Growth in bookings	‡	‡	‡	‡	‡	‡	‡
Organic revenue growth	‡	‡	‡	‡	‡	‡	‡
Overall book-to-bill ratio	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.